Skip to main content
Sinopharm Group Co. Ltd. logo

Sinopharm Group Co. Ltd. — Investor Relations & Filings

Ticker · 1099 ISIN · CNE100000FN7 LEI · 529900N54X78YH9JYK92 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,610 across all filing types
Latest filing 2024-08-26 Board/Management Inform…
Country CN China
Listing HKEX 1099

About Sinopharm Group Co. Ltd.

http://www.sinopharmholding.com

Sinopharm Group Co. Ltd. is a major state-owned enterprise recognized as the largest pharmaceutical logistics provider in Asia and a leading distributor and retailer of healthcare products. The company's core business revolves around providing comprehensive medical supply chain services, encompassing the wholesale and retail distribution of pharmaceuticals, medical devices, and general healthcare products. Sinopharm serves a broad customer base, including hospitals, primary health service institutions, and retail pharmacies. Furthermore, the Group maintains an integrated ecosystem that extends beyond distribution into the manufacturing of pharmaceuticals and chemical reagents, medical services, and industry-finance integration, positioning it as a full-spectrum service provider in the healthcare sector.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT PROPOSED APPOINTMENT OF AUDITORS
Board/Management Information Classification · 95% confidence The document is an announcement regarding the proposed appointment of auditors for the year 2024. It references previous announcements about auditor appointments and retirements, discusses the tendering process for selecting new auditors, and states that the appointment is subject to shareholder approval at an extraordinary general meeting. The document does not contain any financial statements or detailed audit reports but is an announcement about auditor changes and related corporate governance matters. It is not a full audit report (AR) nor an annual report (10-K). It is also not a regulatory filing or report publication announcement since it contains substantive information about auditor appointment. The best fitting category is Board/Management Information (MANG) because it relates to changes in key company roles (auditors) and governance decisions by the board.
2024-08-26 English
ANNOUNCEMENT ON 2024 INTERIM RESULTS
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ANNOUNCEMENT ON 2024 INTERIM RESULTS' and contains detailed unaudited interim condensed consolidated financial statements for the six months ended 30 June 2024, including statements of profit or loss, comprehensive income, financial position, and notes on accounting policies and segment information. The presence of comprehensive financial data and analysis for a half-year period aligns with the characteristics of an Interim / Quarterly Report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or publication notice. Therefore, the document is best classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-26 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-08-21 English
ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE SIX MONTHS ENDED 30 JUNE 2024
Regulatory Filings Classification · 95% confidence The document is an announcement of principal unaudited accounting data and financial indicators for the six months ended 30 June 2024 for Sinopharm (CNCM Ltd), a subsidiary of Sinopharm Group Co. Ltd. It references the 2024 interim report of the subsidiary but does not contain the full interim report itself. The document is relatively short (3863 characters) and serves as a summary announcement of financial data rather than a comprehensive financial report. It is made pursuant to listing rules and includes key financial metrics such as total assets, net profit, revenue, and earnings per share for the reporting period. Given the nature of the document as an announcement of financial data without full financial statements or detailed analysis, and its short length, it fits best as a Regulatory Filing (RNS) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-08-21 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-08-16 English
ANNOUNCEMENT PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD FOR THE SIX MONTHS ENDED 30 JUNE 2024
Regulatory Filings Classification · 95% confidence The document is an announcement of preliminary unaudited financial data for the six months ended 30 June 2024 for Sinopharm Accord, a subsidiary of Sinopharm Group Co. Ltd. It references the reporting period explicitly and provides key financial figures and operational commentary. The document states that the data are preliminary and unaudited, and that the final data will be disclosed in the interim report. The document is about financial results but does not contain full audited financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). It is also not a full Annual Report (10-K) or Earnings Release (ER) since it provides more detailed preliminary data and operational commentary but is explicitly preliminary and unaudited. The document is an announcement of preliminary financial data pursuant to regulatory requirements, which fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement of preliminary financial data rather than the full interim report itself. The document length (5991 characters) and content support this classification rather than a full report or earnings release.
2024-08-16 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.